Regenxbio Inc’s recent filing unveils that its Director KENNETH MILLS acquired Company’s shares for reported $0.15 million on May 12 ’25. In the deal valued at $7.52 per share,20,602 shares were bought.
Then, VITTAL VASISTA bought 20,041 shares, generating $148,504 in total proceeds.
Before that, KARABELAS ARGERIS N sold 10,000 shares. Regenxbio Inc shares valued at $101,052 were divested by the Director at a price of $10.11 per share. As a result of the transaction, KARABELAS ARGERIS N now holds 11,286 shares, worth roughly $92319.48.
Goldman downgraded its Regenxbio Inc [RGNX] rating to a Neutral from a a Buy in a research note published on February 11, 2025; the price target was decreased to $14 from $38.
Price Performance Review of RGNX
On Tuesday, Regenxbio Inc [NASDAQ:RGNX] saw its stock jump 2.63% to $8.18. Over the last five days, the stock has gained 3.28%. Regenxbio Inc shares have risen nearly 5.82% since the year began. Nevertheless, the stocks have fallen -47.83% over the past one year. While a 52-week high of $16.85 was reached on 05/02/25, a 52-week low of $5.03 was recorded on 04/09/25. SMA at 50 days reached $7.42, while 200 days put it at $9.17.
Levels Of Support And Resistance For RGNX Stock
The 24-hour chart illustrates a support level at 7.63, which if violated will result in even more drops to 7.09. On the upside, there is a resistance level at 8.87. A further resistance level may holdings at 9.57. The Relative Strength Index (RSI) on the 14-day chart is 51.88, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.86, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 65.14%. Stochastics %K at 28.24% indicates the stock is a holding.
The most recent change occurred on June 07, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $38 price target.
